Disease stability in COPD

The concept of disease stability in chronic obstructive pulmonary disease (COPD) has recently emerged as a unifying framework to assess treatment response and guide long-term management. Stability is defined by the absence of clinically meaningful deterioration across three key components: symptoms, lung function, and exacerbations. While these parameters are routinely evaluated in clinical practice, the stability framework integrates them into a single, structured approach that supports proactive and individualized management. In this video, Prof Thérèse Laperre and Prof Lowie Vanfleteren, pneumologist at the Antwerp university hospital and the Sahlgrenska University Hospital in Gothenburg, discuss this emerging concept and assess its achievability in the context of COPD.

Symptom stability is typically measured using validated tools such as the COPD Assessment Test (CAT). A change of 2 points or more is considered clinically significant, reflecting true worsening beyond expected day-to-day variability. Therefore, stability in symptoms is defined as maintaining CAT scores within a range that does not exceed this minimal clinically important difference.

Lung function stability is commonly assessed through serial measurements of forced expiratory volume in 1 second (FEV₁). A decline of >100 mL or approximately >5% of the predicted volume is generally regarded as meaningful and may indicate increased disease activity. However, these thresholds must be interpreted in the context of a natural age-related decline and the inherent test–retest variability of spirometry. 

Exacerbation stability requires the complete absence of moderate or severe exacerbations. In fact, even a single moderate exacerbation significantly increases the risk of future events and accelerates lung function loss. Mild, self-managed symptom worsening, such as a brief increase in reliever medication, may occur but is not typically considered a violation of stability unless it reflects a sustained deterioration.

Integrating these three components allows clinicians to interpret patterns of change more holistically. Deterioration across multiple components signals high disease activity and the need for therapeutic escalation, whereas isolated changes in one domain may serve as an early warning sign warranting closer monitoring. 

Assessment intervals should be individualized. Patients with stable disease may be reviewed annually, whereas those with fluctuating symptoms, recent exacerbations, or a rapid FEV₁ decline likely benefit from more frequent monitoring, typically every 3–6 months. Of note, post-exacerbation assessments should take into account that clinical recovery may take several weeks and may not immediately reflect long-term stability.

Emerging imaging techniques and biomarkers may further refine measures of disease activity and stability in the years to come. In addition, more research is needed to validate this concept and translate the stability framework into improved long-term outcomes for patients with COPD.